Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Zidar et al.

The American journal of gastroenterology·2019
Same author

Response to Tursi.

The American journal of gastroenterology·2019
Same author

Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease.

Alimentary pharmacology & therapeutics·2019
Same author

Dual histamine blockade for the treatment of adult functional dyspepsia: a single centre experience.

Gut·2019
Same author

Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers.

British journal of clinical pharmacology·2019
Same author

Follow up on atopy and the gastrointestinal tract - a review of a common association 2018.

Expert review of gastroenterology & hepatology·2019

Related Experiment Video

Updated: Jul 16, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Current treatments in functional dyspepsia.

Meredythe A McNally, Nicholas J Talley

    Current Treatment Options in Gastroenterology
    |March 30, 2007
    PubMed
    Summary

    For functional dyspepsia (FD), testing for Helicobacter pylori or acid suppression therapy is reasonable for uninvestigated cases without alarm features. Endoscopy is crucial for those with alarm signs or new onset over age 55.

    Area of Science:

    • Gastroenterology
    • Internal Medicine

    Background:

    • Functional dyspepsia (FD) diagnosis requires excluding organic causes.
    • Uninvestigated dyspepsia management varies based on alarm features and patient demographics.

    Purpose of the Study:

    • To outline diagnostic and therapeutic strategies for functional dyspepsia.
    • To review evidence for various treatment modalities in FD.

    Main Methods:

    • Review of current guidelines and clinical evidence for FD management.
    • Discussion of diagnostic approaches including endoscopy and H. pylori testing.
    • Evaluation of therapeutic options such as acid suppression, H. pylori eradication, prokinetics, and antidepressants.

    Main Results:

    • Empiric acid suppression (H2RAs, PPIs) is superior to placebo but less effective for meal-related symptoms.

    More Related Videos

    Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
    06:01

    Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

    Published on: July 26, 2024

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
    06:40

    The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

    Published on: June 29, 2019

    Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
    06:01

    Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

    Published on: July 26, 2024

  • Helicobacter pylori eradication benefits a subset of FD patients.
  • Prokinetics may offer benefits for some FD patients, particularly those with meal-related symptoms.
  • Antidepressants are considered for refractory cases, but evidence is limited.

    • Conclusions:

    • Management of FD involves a stepwise approach, starting with empiric treatments for low-risk patients.
    • Endoscopy is essential for high-risk individuals to rule out serious pathology.
    • While H. pylori eradication and acid suppression are common, their efficacy varies; further research is needed for prokinetics and antidepressants.